anti-LILRB2 monoclonal antibody IO-108

{
  "id": "MLC-T-ONC-010864",
  "term": "anti-LILRB2 monoclonal antibody IO-108",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (LILRB2; ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti- LILRB2 monoclonal antibody IO-108 targets and binds to LILRB2. This prevents the binding of LILRB2 ligands to their receptor and prevents LILRB2-mediated signaling. This abrogates the immunosuppressive activities of LILRB2 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. LILRB2, plays a key role in tumor immune evasion. LILRB2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and in certain tumors.",
  "synonyms": [
    "anti-ILT4 monoclonal antibody IO-108"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-lilrb2-monoclonal-antibody-io-108/"
}